US2021093668A1PendingUtilityA1

Nucleic acid constructs comprising gene editing multi-sites and uses thereof

Assignee: IO BIOSCIENCES INCPriority: Feb 22, 2017Filed: Sep 15, 2020Published: Apr 1, 2021
Est. expiryFeb 22, 2037(~10.6 yrs left)· nominal 20-yr term from priority
A61K 40/4211A61K 40/31A61K 40/15C12N 15/66C12N 15/90C07K 14/7051C12N 15/102C07K 2319/02C07K 2319/80C07K 2319/03C12N 2800/102C12N 9/22C07K 16/2803C12N 15/62C07K 2319/70C12N 2800/80A61K 2039/505C07K 2317/622C12N 15/85A61K 35/28A61K 38/00A61K 35/17
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein is a polynucleotide construct comprising one or more nuclease recognition sequences upstream and downstream of a Gene editing multi-site that comprises a plurality of nuclease recognition sequences. The plurality of nuclease recognition sequences facilitate insertion of one or more exogenous donor genes into the host cell.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A method for generating a genetically modified mammalian cell, said method comprising introducing an exogenous nucleic acid sequence that encodes an exogenous protein in a mammalian cell that comprises a GEMS sequence that is inserted within a genome of said mammalian cell,
 wherein said GEMS sequence is heterologous to said genome,   wherein said GEMS sequence comprises a plurality of nuclease recognition sequences that comprises a target sequence and a protospacer adjacent motif (PAM) sequence or reverse complements thereof,   and wherein said exogenous nucleic acid sequence is inserted within at least one of said plurality of nuclease recognition sequences, thereby generating a genetically modified mammalian cell.   
     
     
         3 . The method of  claim 2 , wherein said exogenous protein comprises an antibody, a chimeric antigen receptor (CAR), a T-cell receptor (TCR), a B-cell receptor (BCR), an αβ receptor, a γδ T-receptor, or a combination thereof. 
     
     
         4 . The method of  claim 2 , wherein said mammalian cell is a stem cell. 
     
     
         5 . The method of  claim 4 , wherein said stem cell is an embryonic stem cell, non-embryonic stem cell, pluripotent stem cell, placental stem cell, induced pluripotent stem cell, trophoblast stem cell, adult stem cell, or a hematopoietic stem cell. 
     
     
         6 . The method of  claim 2 , wherein said mammalian cell is a progenitor cell, a T cell, or a natural killer (NK) cell. 
     
     
         7 . The method of  claim 6 , wherein said T cell is a T-cell is an αβ T-cell, an NK T-cell, a γδ T-cell, a regulatory T-cell, a T helper cell and a cytotoxic T-cell. 
     
     
         8 . A genetically modified mammalian cell generated by the method of  claim 2 .

Join the waitlist — get patent alerts

Track US2021093668A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.